Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Goyal P, Vats B, Subbarao M, Honnappa CG, Kabadi P, Rohil S, Bera A, Mehta GR, Pai H, Adhikari L, Tagore R, Sharma S, Venkatachala R, Nair P, Annegowda S, Sahu A, Trivedi S, Shastri N, Gokhale Y, Thomas R, Thakur A, Mohan D, Rao K U, Melarkode R, Ullanat R. Goyal P, et al. Among authors: melarkode r. Expert Opin Biol Ther. 2022 Feb;22(2):271-298. doi: 10.1080/14712598.2021.1973426. Epub 2021 Oct 13. Expert Opin Biol Ther. 2022. PMID: 34465264
Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
Goyal P, Iyer J, Adhikary L, Vats B, Kabadi P, Pai H, Ranayhossaini D, Gouda S, Subbarao M, Mehta G, Saha A, Bera A, Sahu A, Kaur M, Singh A, Marwah A, Reddy Moole PK, Smith J, Melarkode R, Ullanat R. Goyal P, et al. Among authors: melarkode r. Future Med Chem. 2021 Sep;13(18):1531-1557. doi: 10.4155/fmc-2021-0113. Epub 2021 Jul 22. Future Med Chem. 2021. PMID: 34289749
Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
Goyal P, Pai HV, Kodali P, Vats B, Vajpai N, Annegowda S, Mane K, Mohan S, Saxena S, Veerabhadraia AB, Palande M, Nair PS, More DC, Karudumpa UR, Jyothirmai K, Bhattacharya A, Almeida F, Khyade SG, Gouda S, Ranayhossaini DJ, Moole PR, Smith JP, Barve A, Melarkode R, Ullanat R. Goyal P, et al. Among authors: melarkode r. PLoS One. 2021 Jun 16;16(6):e0253168. doi: 10.1371/journal.pone.0253168. eCollection 2021. PLoS One. 2021. PMID: 34133466 Free PMC article.
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, Patel S, Deshchougule AT, S SK, Montero E, Pai HV, Palanivelu DV, Melarkode R, Nair P. Bughani U, et al. Among authors: melarkode r. PLoS One. 2017 Jul 3;12(7):e0180088. doi: 10.1371/journal.pone.0180088. eCollection 2017. PLoS One. 2017. PMID: 28672038 Free PMC article.
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Bughani U, Saha A, Kuriakose A, Nair R, Sadashivarao RB, Venkataraman R, Patel S, Tushar Deshchougule A, Satish KS, Montero E, Pai HV, Palanivelu DV, Melarkode R, Nair P. Bughani U, et al. Among authors: melarkode r. PLoS One. 2018 Jan 30;13(1):e0192335. doi: 10.1371/journal.pone.0192335. eCollection 2018. PLoS One. 2018. PMID: 29381749 Free PMC article.
11 results